AMIPHARM unveiled the clinical phase 3 results of its innovative fat reduction injection AYP-101 at the prestigious IMCAS World Congress 2026 in Paris on Friday. The treatment specifically targets submental fat improvement.
During the conference, AMIPHARM’s Chief Executive Officer (CEO), Lee Gi-taek, highlighted the limitations of existing localized fat reduction injections. He noted that their inflammation-based mechanisms have left unmet needs in terms of safety and recovery time.
Lee emphasized that AYP-101 was developed to address these concerns, aiming to reduce localized fat more safely through mechanisms based on intercellular signaling, lipolysis, and apoptosis.
As a medical aesthetic drug, AYP-101 selectively targets localized fat deposits. It offers a minimally invasive alternative to traditional methods, allowing for simple and convenient procedures without incisions or surgery, thus enhancing both safety and patient comfort.
AMIPHARM successfully completed the phase 3 trial of AYP-101 in December last year. The study, involving 252 participants who received up to six AYP-101 treatments at two-week intervals, yielded promising results. Twelve weeks post-treatment, 73.7% of patients demonstrated an improvement of grade 1 or higher in submental fat, showing statistically significant improvement compared to the placebo group.
The company reported that the presentation sparked considerable interest among attending physicians and multinational pharmaceutical experts, leading to an engaging Q&A session focused on the drug’s mechanism of action and clinical outcomes.
Looking ahead, AMIPHARM plans to expand AYP-101’s indications and bolster its global clinical strategy. Simultaneously, the company is gearing up to make inroads into both domestic and international facial aesthetic markets.
